Hämeenlinna Metabolic Syndrome Research Program: Effects of Rapeseed Oil on Serum Lipids and Platelet Function (HMS-03)

May 6, 2010 updated by: Kanta-Häme Central Hospital

Hämeenlinna Metabolic Syndrome Research Program (HMS): Effects of Dietary Cold-pressed Turnip Rapeseed Oil and Milk Fat on Serum Lipids, Oxidized LDL, Arterial Elasticity and Platelet Function

In this study, the effects of dietary intake of cold-pressed turnip rapeseed oil (CTPRO) and milk fat are compared in men with metabolic syndrome having already participated in HMS-02 study.

Study Overview

Detailed Description

This open and balanced cross-over study consists of two dietary treatment phases (either Virgino (R) CTPRO or butter) for 6 to 8 weeks. They are separated from each other with an eight-week washout period. At the end of both periods and 12-hour fasting an oral glucose-fat tolerance test is carried out. Except glucose, the test consists cream (after the butter phase) and CTPRO (after the CTPRO phase).

Otherwise, the subjects (n=43) are asked to maintain their normal dietary habits.

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, 00310
        • Finnish Red Cross Blood Transfusion Service
      • Hämeenlinna, Finland, 13100
        • Linnan Klinikka
      • Hämeenlinna, Finland, 13530
        • Central Hospital of Kanta-Häme
      • Jokioinen, Finland, 31600
        • MTT Agrifood Research Finland

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

31 years to 66 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • 43 men with metabolic syndrome having already participated in the HMS-02 Study
  • Willing to participate in a demanding dietary study

Exclusion Criteria:

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Rapeseed oil
  1. In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.
  2. In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO.
Other Names:
  • Virgino
ACTIVE_COMPARATOR: Milk fat
  1. In dietary period of 6 to 8 weeks: 37.5 grams of butter.
  2. In the 5-hour oral glucose and fat tolerance test: glucose and cream
Other Names:
  • Valio butter

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Circulating lipids
Time Frame: 6 to 8 weeks
At the end of both 6- to 8-week dietary periods, fasting values of circulating lipids including oxidized LDL are determined
6 to 8 weeks
Platelet function
Time Frame: 6 to 8 weeks
At the end of both 6- to 8-week dietary periods, platelet function is determined
6 to 8 weeks
Glucose tolerance
Time Frame: 5 hours
During a 5-hour oral glucose-fat tolerance test the area under curve of plasma glucose and insulin concentration is determined
5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arterial elasticity
Time Frame: 6 to 8 weeks
At the end of both 6- to 8-week dietary periods, arterial elasticity is determined
6 to 8 weeks
Serum triglyceride AUC
Time Frame: 5 hours
During a 5-hour oral glucose-fat tolerance test the area under curve of serum triglyceride concentration is determined
5 hours
Platelet function
Time Frame: 5 hours
During a 5-hour oral glucose-fat tolerance test the platelet function is determined
5 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2004

Primary Completion (ACTUAL)

April 1, 2005

Study Completion (ACTUAL)

June 1, 2008

Study Registration Dates

First Submitted

May 6, 2010

First Submitted That Met QC Criteria

May 6, 2010

First Posted (ESTIMATE)

May 7, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

May 7, 2010

Last Update Submitted That Met QC Criteria

May 6, 2010

Last Verified

May 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

3
Subscribe